☰

John M. Maris - Publications

Affiliations: 
Genomics and Computational Biology University of Pennsylvania, Philadelphia, PA, United States 
Area:
Oncology, Biostatistics Biology, Bioinformatics Biology
Tree Info Similar researchers PubMed Report error

364 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Lopez G, Conkrite KL, Doepner M, Rathi KS, Modi A, Vaksman Z, Farra L, Hyson E, Noureddine M, Wei JS, Smith MA, Asgharzadeh S, Seeger R, Khan JS, Guidry Auvil JM, ... ... Maris JM, et al. Somatic structural variation targets neurodevelopmental genes and identifies as a tumor suppressor in neuroblastoma. Genome Research. PMID 32796005 DOI: 10.1101/Gr.252106.119  0.419
2020 Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A, Schleiermacher G, Speleman F, Chesler L, Geoerger B, Hogarty MD, Irwin MS, Bird N, Blanchard GB, ... ... Maris JM, et al. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 136: 52-68. PMID 32653773 DOI: 10.1016/J.Ejca.2020.05.010  0.306
2020 Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota JG, ... ... Maris JM, et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine. PMID 32341580 DOI: 10.1038/S41591-020-0827-2  0.301
2020 Chen D, Cox J, Annam J, Weingart M, Essien G, Rathi KS, Rokita JL, Khurana P, Cuya SM, Bosse KR, Pilgrim A, Li D, Shields C, Laur O, Maris JM, et al. LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase. Neoplasia (New York, N.Y.). 22: 231-241. PMID 32339949 DOI: 10.1016/J.Neo.2020.04.001  0.322
2020 Healy JR, Hart LS, Shazad AL, Gagliardi ME, Tsang M, Elias J, Ruden J, Farrel A, Rokita JL, Li Y, Wyce A, Barbash O, Batra V, Samanta M, Maris JM, et al. Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma. Pediatric Blood & Cancer. e28267. PMID 32307821 DOI: 10.1002/Pbc.28267  0.317
2020 Koneru B, Lopez G, Farooqi A, Conkrite KL, Nguyen TH, Macha SJ, Modi A, Rokita JL, Urias E, Hindle A, Davidson H, Mccoy K, Nance J, Yazdani V, Irwin MS, ... ... Maris JM, et al. Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma. Cancer Research. PMID 32291317 DOI: 10.1158/0008-5472.Can-19-3068  0.387
2020 Sussman RT, Rokita JL, Huang K, Raman P, Rathi KS, Martinez D, Bosse KR, Lane M, Hart LS, Bhatti T, Pawel B, Maris JM. CAMKV Is a Candidate Immunotherapeutic Target in Amplified Neuroblastoma. Frontiers in Oncology. 10: 302. PMID 32211329 DOI: 10.3389/Fonc.2020.00302  0.341
2020 Li Y, Gruber JJ, Litzenburger UM, Zhou Y, Miao YR, LaGory EL, Li AM, Hu Z, Yip M, Hart LS, Maris JM, Chang HY, Giaccia AJ, Ye J. Acetate supplementation restores chromatin accessibility and promotes tumor cell differentiation under hypoxia. Cell Death & Disease. 11: 102. PMID 32029721 DOI: 10.1038/S41419-020-2303-9  0.311
2020 Kolb EA, Houghton PJ, Kurmasheva RT, Mosse YP, Maris JM, Erickson SW, Guo Y, Teicher BA, Smith MA, Gorlick R. Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. Pediatric Blood & Cancer. e28098. PMID 31975571 DOI: 10.1002/Pbc.28098  0.37
2020 DuBois SG, Kremer JD, De Wilde B, Jacobsen C, Aerts I, Mosse YP, Maris JM, Lithio A, Gosberg A, Banks C, Tate C, Dowless M, Gong X, Stancato L, Bell-McGuinn KM, et al. A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma. Journal of Clinical Oncology. 38: TPS10561-TPS10561. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps10561  0.387
2020 Zhao X, Li MM, Schubert J, Wu J, Lin F, Wertheim GB, Surrey L, Luo M, Zhong Y, Wu C, Cao K, Aplenc R, Bagatell R, Mosse YP, Olson TS, ... ... Maris JM, et al. Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients. Journal of Clinical Oncology. 38: e13666-e13666. DOI: 10.1200/Jco.2020.38.15_Suppl.E13666  0.402
2020 Goldsmith KC, Kayser K, Groshen SG, Chioda M, Thurm HC, Chen J, Peltz G, Granger M, Maris J, Matthay KK, Ghazarian S, Park JR, Berko E, Marachelian A, Mosse YP. Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study. Journal of Clinical Oncology. 38: 10504-10504. DOI: 10.1200/Jco.2020.38.15_Suppl.10504  0.316
2020 Chen D, Cox J, Annam J, Weingart M, Essien G, Rathi K, Khurana P, Cuya S, Harenza JL, Bosse K, Pilgrim A, Maris JM, Schnepp RW. Abstract B48: A LIN28B-PDZ kinase axis promotes neuroblastoma metastasis Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-B48  0.411
2020 Bosse KR, Raman S, Buongervino S, Lane M, Upton K, Cui H, Martinez B, Martinez D, Zhelev DV, Pawel B, Dimitrov DS, Julien J, Maris JM. Abstract A26: Characterization and development of a GPC2 ADC for neuroblastoma and other cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A26  0.397
2020 Heitzeneder S, Bosse KR, Zhu Z, Majzner RG, Theruvath J, Xu P, Dhingra S, Anbunathan H, Alag A, Dimitrov DS, Maris JM, Mackall CL. Abstract A09: Glypican-2 targeted CAR T cells designed to effectively eradicate endogenous site density solid tumors in the absence of toxicity Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A09  0.391
2020 Nunga L, Schwalbe E, Lafta F, Tweddle D, Maris J, Barrow T, Strathdee G. Abstract 1275: Identification of cancer-specific synthetic lethal genes as novel therapeutic targets Cancer Research. 80: 1275-1275. DOI: 10.1158/1538-7445.Am2020-1275  0.346
2019 Yarmarkovich M, Maris JM. When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors Cancer Cell. 36: 575-576. PMID 31951557 DOI: 10.1016/J.Ccell.2019.11.006  0.324
2019 Voeller J, Erbe AK, Slowinski J, Rasmussen K, Carlson PM, Hoefges A, VandenHeuvel S, Stuckwisch A, Wang X, Gillies SD, Patel RB, Farrel A, Rokita JL, Maris J, Hank JA, et al. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. Journal For Immunotherapy of Cancer. 7: 344. PMID 31810498 DOI: 10.1186/S40425-019-0823-6  0.354
2019 Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, ... ... Maris JM, et al. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports. 29: 1675-1689.e9. PMID 31693904 DOI: 10.1016/J.Celrep.2019.09.071  0.394
2019 Lee H, Riad A, Martorano P, Mansfield A, Samanta M, Batra V, Mach RH, Maris JM, Pryma DA, Makvandi M. PARP-1-targeted Auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31676730 DOI: 10.2967/Jnumed.119.233965  0.36
2019 Qadeer ZA, Valle-Garcia D, Hasson D, Sun Z, Cook A, Nguyen C, Soriano A, Ma A, Griffiths LM, Zeineldin M, Filipescu D, Jubierre L, Chowdhury A, Deevy O, Chen X, ... ... Maris JM, et al. ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. Cancer Cell. PMID 31631027 DOI: 10.1016/J.Ccell.2019.09.002  0.302
2019 Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, Ibrahim F, Maragkakis M, Gazzara MR, Black KL, Bagashev A, Taylor D, Mourelatos Z, Grupp SA, Barrett D, ... Maris JM, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. PMID 31591467 DOI: 10.1038/S41375-019-0580-Z  0.558
2019 Foster JB, Madsen PJ, Hegde M, Ahmed N, Cole KA, Maris JM, Resnick AC, Storm PB, Waanders AJ. Immunotherapy for pediatric brain tumors: past and present. Neuro-Oncology. PMID 31504801 DOI: 10.1093/Neuonc/Noz077  0.344
2019 Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, ... ... Maris JM, et al. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900919. PMID 31386611 DOI: 10.1200/Jco.19.00919  0.302
2019 Surrey LF, MacFarland SP, Chang F, Cao K, Rathi KS, Akgumus GT, Gallo D, Lin F, Gleason A, Raman P, Aplenc R, Bagatell R, Minturn J, Mosse Y, Santi M, ... ... Maris JM, et al. Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Medicine. 11: 32. PMID 31133068 DOI: 10.1186/S13073-019-0644-8  0.334
2019 Oldridge DA, Truong B, Russ D, DuBois SG, Vaksman Z, Mosse YP, Diskin SJ, Maris JM, Matthay KK. Differences in Genomic Profiles and Outcomes between Thoracic and Adrenal Neuroblastoma. Journal of the National Cancer Institute. PMID 30793172 DOI: 10.1093/Jnci/Djz027  0.334
2019 Mlakar V, Jurkovic Mlakar S, Lesne L, Marino D, Rathi KS, Maris JM, Ansari M, Gumy-Pause F. PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level. Journal of Experimental & Clinical Cancer Research : Cr. 38: 69. PMID 30755224 DOI: 10.1186/S13046-019-1066-6  0.358
2019 Hill-Kayser CE, Tochner Z, Li Y, Kurtz G, Lustig RA, James P, Balamuth N, Womer R, Mattei P, Grupp S, Mosse YP, Maris JM, Bagatell R. Outcomes after Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. International Journal of Radiation Oncology, Biology, Physics. PMID 30738983 DOI: 10.1016/J.Ijrobp.2019.01.095  0.304
2019 Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, Pollak M, Noer PR, Lorette J, Fazli L, Alag A, Meltzer P, Lau C, Conover CA, Oxvig C, ... ... Maris JM, et al. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. Journal of the National Cancer Institute. PMID 30698726 DOI: 10.1093/Jnci/Djy209  0.325
2019 Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, ... ... Maris JM, et al. CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30655315 DOI: 10.1158/1078-0432.Ccr-18-0432  0.385
2019 Irwin M, Naranjo A, Cohn SL, London WB, Gastier-Foster JM, Maris JM, Bagatell R, Park JR, Hogarty MD. A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1. Journal of Clinical Oncology. 37: 10012-10012. DOI: 10.1200/Jco.2019.37.15_Suppl.10012  0.312
2019 Earley E, Gorlick R, Houghton PJ, Maris JM, Li X, Lock RB, Teicher B, Smith MA, Erickson SW. Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-321  0.337
2019 Weiner AK, Radaoui AB, Kendsersky NM, Harenza-Rokita JL, Sidoli S, Conkrite KL, Vaksman Z, Rathi K, Raman P, Martinez D, Bhatti T, Tsang M, Pawel B, Garcia BA, Maris JM, et al. Abstract 3650: Integrative mass spectrometry and RNA-sequencing identifies DLK1 as a candidate immunotherapeutic target in neuroblastoma Cancer Research. 79: 3650-3650. DOI: 10.1158/1538-7445.Am2019-3650  0.349
2019 Weiner AK, Radaoui AB, Tsang M, Martinez D, Sidoli S, Conkrite KL, Delaidelli A, Rokita JL, Lane MV, Vaksman Z, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, ... ... Maris JM, et al. Abstract LB-B04: A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Lb-B04  0.389
2019 Kurmasheva R, Kolb EA, Smith MA, Teicher BA, Erickson SW, Maris JM, Mosse YP, Krytska K, Groff D, Tang M, Wang Y, Croix BS, Gorlick R, Houghton PJ. Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC) Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C003  0.374
2018 Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Bence Lin A, P Beckmann R, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, et al. Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30563935 DOI: 10.1158/1078-0432.Ccr-18-2728  0.384
2018 Cimmino F, Avitabile M, Diskin SJ, Vaksman Z, Pignataro P, Formicola D, Cardinale A, Testori A, Koster J, de Torres C, Devoto M, Maris JM, Iolascon A, Capasso M. Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. International Journal of Cancer. PMID 30132831 DOI: 10.1002/Ijc.31822  0.336
2018 Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Nagaraj S, Walton A, Guidry Auvil JM, Gerhard DS, Yuksel A, Catchpoole DR, Hewitt SM, ... ... Maris JM, et al. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk -not-amplified Human Neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29784674 DOI: 10.1158/1078-0432.Ccr-18-0599  0.34
2018 Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, ... ... Maris JM, et al. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute. PMID 29514301 DOI: 10.1093/Jnci/Djy022  0.315
2018 Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, ... ... Maris JM, et al. Cross-cohort analysis identifies a TEAD4 ↔ MYCN positive-feedback loop as the core regulatory element of high-risk neuroblastoma. Cancer Discovery. PMID 29510988 DOI: 10.1158/2159-8290.Cd-16-0861  0.342
2018 Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, ... ... Maris JM, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. PMID 29489755 DOI: 10.1038/Nature25795  0.324
2018 Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, ... Maris JM, et al. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget. 9: 6416-6432. PMID 29464082 DOI: 10.18632/Oncotarget.23740  0.338
2018 Toor JS, Rao AA, McShan AC, Yarmarkovich M, Nerli S, Yamaguchi K, Madejska AA, Nguyen S, Tripathi S, Maris JM, Salama SR, Haussler D, Sgourakis NG. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations. Frontiers in Immunology. 9: 99. PMID 29441070 DOI: 10.3389/Fimmu.2018.00099  0.328
2018 Deveau P, Colmet Daage L, Oldridge D, Bernard V, Bellini A, Chicard M, Clement N, Lapouble E, Combaret V, Boland A, Meyer V, Deleuze JF, Janoueix-Lerosey I, Barillot E, Delattre O, ... Maris J, et al. QuantumClone: Clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. Bioinformatics (Oxford, England). PMID 29342233 DOI: 10.1093/Bioinformatics/Bty016  0.32
2018 Harenza JL, Chen G, Maris JM. Abstract B24: Characterization of somatically acquired regulatory mutations in high-risk neuroblastoma Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-B24  0.376
2018 Sano R, Krytska K, Tsang M, Erickson SW, Teicher BA, Saunders L, Jones RT, Smith MA, Maris JM, Mosse YP. Abstract LB-136: Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-136  0.389
2018 Bosse KR, Zhu Z, Lane M, Martinez D, DeLong J, Zhelev DV, Feng Y, Wang Y, Hwang J, Dimitrov DS, Maris J. Abstract 4636: The antibody-drug conjugate D3-GPC2-PBD potently eradicates neuroblastoma patient-derived xenografts Cancer Research. 78: 4636-4636. DOI: 10.1158/1538-7445.Am2018-4636  0.348
2018 Rosati R, Swan HA, Scolaro L, Krytska K, Maris JM, Schaub FX, Grandori C. Abstract 2625: Patient derived organoids to guide personalized neuroblastoma treatment Cancer Research. 78: 2625-2625. DOI: 10.1158/1538-7445.Am2018-2625  0.369
2018 Houghton PJ, Kurmasheva RT, Gorlick R, Kolb EA, Mosse YP, Erickson SW, Guo Y, Teicher BA, Smith MA, Maris JM. Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-B15  0.397
2018 Krytska K, Evans K, Pritchard T, Tsang M, Yung R, Mosse YP, Erickson SW, Guo Y, Baloglu E, Landesman Y, Jensen KA, Senapedis W, Teicher BA, Smith MA, Lock RB, ... Maris JM, et al. Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602 Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-B14  0.406
2018 Cole KA, Houghton PJ, Kurmasheva RT, Gorlick R, Kolb EA, Kang M, Reynolds CP, Li X, Lindsay H, Erickson SW, Guo Y, Teicher BA, Smith MA, Maris JM. Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-B13  0.399
2018 Delaidelli A, Negri GL, Sidhu S, Cran J, Remke M, Pfister S, Kool M, Taylor M, Maris J, Leprivier G, Sorensen P. Mbrs-57. Targeting Metabolic Adaptation In Myc/Mycn Amplified Pediatric Medulloblastoma And Neuroblastoma Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.501  0.396
2017 Hungate EA, Applebaum MA, Skol AD, Vaksman Z, Diamond M, McDaniel L, Volchenboum SL, Stranger BE, Maris JM, Diskin SJ, Onel K, Cohn SL. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. Journal of the National Cancer Institute. 109. PMID 29117357 DOI: 10.1093/Jnci/Djx093  0.315
2017 Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, ... ... Maris JM, et al. Comprehensive Analysis of Hypermutation in Human Cancer. Cell. PMID 29056344 DOI: 10.1016/J.Cell.2017.09.048  0.367
2017 Erbe AK, Wang W, Carmichael L, Kim K, Mendonca EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, ... ... Maris JM, et al. Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28972044 DOI: 10.1158/1078-0432.Ccr-17-1767  0.305
2017 Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, ... ... Maris JM, et al. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell. 32: 295-309.e12. PMID 28898695 DOI: 10.1016/J.Ccell.2017.08.003  0.348
2017 Zhu S, Zhang X, Weichert-Leahey N, Dong Z, Zhang C, Lopez G, Tao T, He S, Wood AC, Oldridge D, Ung CY, van Ree JH, Khan A, Salazar BM, Lummertz da Rocha E, ... ... Maris JM, et al. LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell. PMID 28867147 DOI: 10.1016/J.Ccell.2017.08.002  0.353
2017 Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, et al. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in Immunology. 8: 675. PMID 28659916 DOI: 10.3389/Fimmu.2017.00675  0.31
2017 Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel BR, Santi M, Merchant MS, Geoerger B, Hezam I, Marty V, Vielh P, Daugaard M, Sorensen PH, Mackall CL, Maris JM. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer. PMID 28608950 DOI: 10.1002/Cncr.30724  0.321
2017 Delaidelli A, Negri GL, Jan A, Jansonius B, El-Naggar A, Lim JKM, Khan D, Zarni Oo H, Carnie CJ, Remke M, Maris JM, Leprivier G, Sorensen PH. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. Cell Death and Differentiation. PMID 28574509 DOI: 10.1038/Cdd.2017.79  0.413
2017 Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. The Lancet. Oncology. PMID 28549783 DOI: 10.1016/S1470-2045(17)30355-8  0.306
2017 Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016720177. PMID 28471719 DOI: 10.1200/Jco.2016.72.0177  0.31
2017 Tolbert VP, Coggins GE, Maris JM. Genetic susceptibility to neuroblastoma. Current Opinion in Genetics & Development. 42: 81-90. PMID 28458126 DOI: 10.1016/J.Gde.2017.03.008  0.31
2017 DuBois SG, Mody R, Naranjo A, Van Ryn C, Russ D, Oldridge D, Kreissman S, Baker DL, Parisi M, Shulkin BL, Bai H, Diskin SJ, Batra V, Maris JM, Park JR, et al. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood & Cancer. PMID 28383813 DOI: 10.1002/Pbc.26545  0.308
2017 Harenza JL, Diamond MA, Adams RN, Song MM, Davidson HL, Hart LS, Dent MH, Fortina P, Reynolds CP, Maris JM. Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Scientific Data. 4: 170033. PMID 28350380 DOI: 10.1038/Sdata.2017.33  0.321
2017 Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S, Spritz D, Ali S, Gay L, Erlich RL, Ross JS, ... ... Maris JM, et al. Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Research. PMID 28069802 DOI: 10.1158/0008-5472.Can-16-1106  0.401
2017 Desantes K, Maris JM, McDowell K, Mackall C, Shankar S, Vasselli J, Chen F, Loo D, Moore PA, Wigginton JM, Sondel PM. A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors. Journal of Clinical Oncology. 35: TPS2596-TPS2596. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2596  0.379
2017 Makvandi M, Hou C, Xu K, Anderson R, Ander-Effron S, Mach RH, Maris JM, Pryma DA. Abstract B31: Poly(ADP-ribose) Polymerase 1 as a novel target for alpha-particle therapy in high-risk neuroblastoma Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B31  0.345
2017 Cole KA, Reid JM, Liu X, Minard CG, Maris JM, Fox E, Weigel BJ. Abstract CT144: Pediatric phase I trial of the WEE1 inhibitor AZD1775 and irinotecan in patients with refractory solid and CNS malignancies; A Children’s Oncology Group Study (ADVL1312) Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct144  0.334
2017 Vaksman Z, McDaniel LD, Diamond M, Maris JM, Diskin SJ. Abstract 690: Identifying the genetic basis of stage 4S neuroblastoma Cancer Research. 77: 690-690. DOI: 10.1158/1538-7445.Am2017-690  0.312
2017 Batra V, Elias J, Makvandi M, Tsang M, Ranieri P, Hou C, Li Y, Pryma DA, Maris JM. Abstract 688: Meta-[211At]astatobenzylguanidine ([211At]MABG) is a potent alpha particle emitting systemic targeted radiotherapeutic in preclinical models of neuroblastoma Cancer Research. 77: 688-688. DOI: 10.1158/1538-7445.Am2017-688  0.367
2017 Bosse KR, Raman P, Lane M, Sussman RT, Harenza JL, Martinez D, Heitzeneder S, Zhu Z, Rathi K, Randall M, Donovan L, Morrissy S, Zhelev DV, Feng Y, Hwang J, ... ... Maris JM, et al. Abstract 685: GPC2 is an oncogene and immunotherapeutic target in high-risk neuroblastoma Cancer Research. 77: 685-685. DOI: 10.1158/1538-7445.Am2017-685  0.394
2017 Weiner AK, Sidoli S, Glisovic-Aplenc T, Maris JM, Garcia BA, Diskin SJ. Abstract 684: Integrative proteomics and transcriptomics to define the cell surface landscape of neuroblastoma Cancer Research. 77: 684-684. DOI: 10.1158/1538-7445.Am2017-684  0.328
2017 Yarmarkovich M, Marco MD, Padovan O, Lobby J, Eisenlohr L, Monos D, Stevanovic S, Maris JM. Abstract 5824: MHC class I immunogenicity and novel tumor antigen discovery in neuroblastoma Cancer Research. 77: 5824-5824. DOI: 10.1158/1538-7445.Am2017-5824  0.301
2017 Puentes L, Xu K, Hou C, Mach RH, Maris JM, Pryma DA, Makvandi M. Abstract 5197: Targeting PARP-1 to deliver alpha-particles to cancer chromatin Cancer Research. 77: 5197-5197. DOI: 10.1158/1538-7445.Am2017-5197  0.397
2017 Lopez G, Conkrite K, Hong K, Harenza JL, Maris JM, Diskin S. Abstract 4881: Dissecting telomere maintenance mechanisms in neuroblastoma Cancer Research. 77: 4881-4881. DOI: 10.1158/1538-7445.Am2017-4881  0.394
2017 Ma X, Liu Y, Liu Y, Edmonson M, Gawad C, Zhou X, Li Y, Rusch M, Easton J, Wilkinson M, Hermida LC, Davis S, Smith M, Auvil JG, Meltzer P, ... ... Maris JM, et al. Abstract 3004: Comparison of somatic alterations in the genome and transcriptome of 1,705 pediatric leukemia and solid tumors: a report from the Children’s Oncology Group (COG) - NCI TARGET Project Cancer Research. 77: 3004-3004. DOI: 10.1158/1538-7445.Am2017-3004  0.384
2017 Harenza JL, Diamond MA, Oldridge DA, Padovan-Merher O, Raman P, Mosse YP, Maris JM. Abstract 3000: Defining the subclonal landscape of high-risk neuroblastoma Cancer Research. 77: 3000-3000. DOI: 10.1158/1538-7445.Am2017-3000  0.37
2017 Delaidelli A, Negri GL, Jan A, Jansonius B, Lim JKM, Leprivier G, Kool M, Pfister SM, Remke M, Taylor M, Maris JM, Sorensen PH. Pdtm-46. Targeting Metabolic Adaptation In Myc Driven Pediatric Neuronal Tumors Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.808  0.396
2017 Huang M, Zheng T, Guo J, Sperring C, Miller M, McHenry L, Zhen Q, Moriarity B, Bronner M, Conklin B, Largaespada D, Maris J, Matthay K, Weiss W. TMOD-09. HUMAN PLURIPOTENT STEM CELL-BASED MODELS OF NEUROBLASTOMA Neuro-Oncology. 19: vi256-vi256. DOI: 10.1093/Neuonc/Nox168.1048  0.391
2016 Padovan-Merhar OM, Raman P, Ostrovnaya I, Kalletla K, Rubnitz KR, Sanford EM, Ali SM, Miller VA, Mossé YP, Granger MP, Weiss B, Maris JM, Modak S. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. Plos Genetics. 12: e1006501. PMID 27997549 DOI: 10.1371/Journal.Pgen.1006501  0.363
2016 Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA. Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. PMID 27786412 DOI: 10.1002/Pbc.26304  0.382
2016 Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, ... ... Maris JM, et al. Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27729458 DOI: 10.1158/1078-0432.Ccr-16-1131  0.323
2016 Batra V, Makvandi M, Zuppa AF, Patel N, Elias J, Pryma DA, Maris JM. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations. Pediatric Blood & Cancer. PMID 27654664 DOI: 10.1002/Pbc.26268  0.315
2016 Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, Maris JM, Weiss B, Marachelian A, Yanik GA, Matthay KK. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. European Journal of Cancer (Oxford, England : 1990). 66: 144-152. PMID 27573428 DOI: 10.1016/J.Ejca.2016.07.017  0.303
2016 Yagyu S, Iehara T, Tanaka S, Gotoh T, Misawa-Furihata A, Sugimoto T, London WB, Hogarty MD, Teramukai S, Nakagawara A, Hiyama E, Maris JM, Hosoi H. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. Plos One. 11: e0161039. PMID 27513929 DOI: 10.1371/Journal.Pone.0161039  0.356
2016 Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, et al. Evaluation of Alternative In Vivo Drug Screening Methodology: single mouse analysis. Cancer Research. PMID 27496711 DOI: 10.1158/0008-5472.Can-16-0122  0.353
2016 Liu Z, Lam N, Wang E, Virden RA, Pawel B, Attiyeh EF, Maris JM, Thiele CJ. Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma. Oncogene. PMID 27270431 DOI: 10.1038/Onc.2016.179  0.332
2016 Kang MH, Reynolds CP, Kolb EA, Gorlick R, Carol H, Lock R, Keir ST, Maris JM, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. PMID 27238606 DOI: 10.1002/Pbc.26064  0.339
2016 Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, et al. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatric Blood & Cancer. PMID 27092812 DOI: 10.1002/Pbc.25994  0.312
2016 Feng Y, Wang Y, Zhu Z, Sussman RT, Randall M, Bosse KR, Maris JM, Dimitrov DS, Li W. Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes. Mabs. 0. PMID 26910291 DOI: 10.1080/19420862.2016.1155014  0.303
2016 Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, Scharl M, Aguzzi A, Oldrige DA, Maris JM, Rogler G. Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. Plos One. 11: e0147682. PMID 26821351 DOI: 10.1371/Journal.Pone.0147682  0.336
2016 Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 63: 443-50. PMID 26797892 DOI: 10.1002/Pbc.25826  0.413
2016 Bosse KR, Maris JM. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer. 122: 20-33. PMID 26539795 DOI: 10.1002/Cncr.29706  0.389
2016 Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Geiger JD, Doski JJ, Gorges SW, Khanna G, Voss SD, Maris JM, et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. Journal of Clinical Oncology. 34: LBA3-LBA3. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba3  0.324
2016 Majzner RG, Martinez D, Pawel B, Santi M, Sorensen P, Mackall C, Maris JM. Assessment of PD-L1 expression and tumor associated immune cells in pediatric cancer tissues. Journal of Clinical Oncology. 34: 11542-11542. DOI: 10.1200/Jco.2016.34.15_Suppl.11542  0.306
2016 DuBois SG, Mody R, Van Ryn C, Naranjo A, Kreissman SG, Baker D, Parisi MT, Shulkin BL, Maris JM, Batra V, Park JR, Matthay KK, Yanik GA. Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG). Journal of Clinical Oncology. 34: 10526-10526. DOI: 10.1200/Jco.2016.34.15_Suppl.10526  0.316
2016 Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes S, Dicciani MB, Sondel PM, Maris JM, Park JR, Bagatell R. Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Children’s Oncology Group (COG). Journal of Clinical Oncology. 34: 10502-10502. DOI: 10.1200/Jco.2016.34.15_Suppl.10502  0.307
2016 Bosse KR, Raman P, Sussman RT, Randall M, Martinez D, Zhu Z, Pawel B, Bhatti T, Khan J, Dimitrov DS, Mackall C, Maris JM. Abstract PR02: GPC2 is a candidate immunotherapeutic target and putative oncogene in high-risk neuroblastoma and other pediatric cancers Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Pr02  0.418
2016 Hart LS, Raman P, Coggins G, Rader J, Maris JM. Abstract LB-126: The identification of synthetic lethal partners cooperating with MEK1/2 inhibition in neuroblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-126  0.386
2016 Rajbhandari P, Lopez G, Yu J, Rodriguez-Barrueco R, Alvarez M, Martinez D, Yarmarkovich M, Vandesompele J, Mestdagh P, Silva JM, Lasorella A, Iavarone A, Maris JM, Califano A. Abstract 4384: Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk neuroblastoma subtype state maintenance Cancer Research. 76: 4384-4384. DOI: 10.1158/1538-7445.Am2016-4384  0.398
2016 Harenza JL, Sussman R, Oldridge D, Maris J. Abstract 2425: Genome-wide mapping of MYCN, MYC, and MAX binding across neuroblastoma cell lines identifies novel transcriptional targets Cancer Research. 76: 2425-2425. DOI: 10.1158/1538-7445.Am2016-2425  0.38
2016 Sanda T, Akahanse K, Abraham BJ, Weichert N, Durbin A, Anders L, Tan SH, Yam AWY, Lawton LN, Young RA, Maris JM, Look AT. Abstract 2007: Transcriptional regulatory program controlled by the oncogenic transcription factor LMO1 in neuroblastoma Cancer Research. 76: 2007-2007. DOI: 10.1158/1538-7445.Am2016-2007  0.36
2016 Wei JS, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Auvil JMG, Gerhard DS, Seeger R, Maris JM, Khan J. Abstract 126: The transcriptome landscape of high-risk neuroblastoma Cancer Research. 76: 126-126. DOI: 10.1158/1538-7445.Am2016-126  0.427
2015 Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, ... ... Maris JM, et al. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Letters. PMID 26683771 DOI: 10.1016/J.Canlet.2015.11.045  0.355
2015 Maris JM. Defining Why Cancer Develops in Children. The New England Journal of Medicine. 373: 2373-5. PMID 26580096 DOI: 10.1056/Nejme1513921  0.328
2015 Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, Winter C, McDaniel LD, Diamond M, Hart LS, Zhu S, Durbin AD, Abraham BJ, Anders L, Tian L, Zhang S, ... ... Maris JM, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature. PMID 26560027 DOI: 10.1038/Nature15540  0.308
2015 Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, ... ... Maris JM, et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery. PMID 26516065 DOI: 10.1158/2159-8290.Cd-15-1020  0.589
2015 Schnepp RW, Khurana P, Attiyeh EF, Raman P, Chodosh SE, Oldridge DA, Gagliardi ME, Conkrite KL, Asgharzadeh S, Seeger RC, Madison BB, Rustgi AK, Maris JM, Diskin SJ. A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. Cancer Cell. 28: 599-609. PMID 26481147 DOI: 10.1016/J.Ccell.2015.09.012  0.315
2015 Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, et al. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatric Blood & Cancer. PMID 26398108 DOI: 10.1002/Pbc.25727  0.336
2015 Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatric Blood & Cancer. PMID 26154614 DOI: 10.1002/Pbc.25611  0.402
2015 Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatric Blood & Cancer. 62: 1739-46. PMID 26153194 DOI: 10.1002/Pbc.25594  0.32
2015 Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, ... ... Maris JM, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics. PMID 26121087 DOI: 10.1038/Ng.3333  0.349
2015 Russell MR, Penikis A, Oldridge DA, Alvarez-Dominguez JR, McDaniel L, Diamond M, Padovan O, Raman P, Li Y, Wei JS, Zhang S, Gnanchandran J, Seeger R, Asgharzadeh S, Khan J, ... ... Maris JM, et al. CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Research. PMID 26100672 DOI: 10.1158/0008-5472.Can-14-3613  0.384
2015 Mandriota SJ, Valentijn LJ, Lesne L, Betts DR, Marino D, Boudal-Khoshbeen M, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, et al. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget. 6: 18558-76. PMID 26053094 DOI: 10.18632/Oncotarget.4061  0.364
2015 Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM, Smith MA. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood & Cancer. 62: 1214-21. PMID 25809532 DOI: 10.1002/Pbc.25474  0.341
2015 Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, et al. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 673-81. PMID 25639769 DOI: 10.1016/J.Bbmt.2014.12.008  0.324
2015 Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 819-32. PMID 25500058 DOI: 10.1158/1078-0432.Ccr-14-2572  0.367
2015 Attiyeh EF, Maris JM. Identifying rare events in rare diseases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1782-5. PMID 25424848 DOI: 10.1158/1078-0432.Ccr-14-2314  0.339
2015 Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 62: 1106-9. PMID 25407467 DOI: 10.1002/Pbc.25329  0.385
2015 Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatric Blood & Cancer. 62: 91-8. PMID 25263539 DOI: 10.1002/Pbc.25201  0.403
2015 Maris JM. Abstract IA04: Neuroblastoma as a paradigm of MYC(N) driven cancers Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Ia04  0.351
2015 Healy JR, Schnepp RW, Hart LS, Raman P, Danielson L, Russell M, Khurana P, Gagliardi M, Kinsey RM, Wyce A, Barbash O, Tummino PJ, Chesler L, Maris JM. Abstract B34: Antitumor activity and sensitivity evaluation of novel BET inhibitors in neuroblastoma Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B34  0.413
2015 Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H. Abstract A37: Immunohistochemical detection of MYCN protein and MYC protein identifies highly aggressive neuroblastomas Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-A37  0.361
2015 Lopez G, Alvarez M, Chen J, Rajbhandari P, Cole KA, Attiyeh EF, Diskin S, Mestdagh P, Vandesompele J, Maris JM, Califano A. Abstract PR10: Oncogenic dysregulations in neuroblastoma are associated with distal large chromosomal aberrations Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-Pr10  0.357
2015 Ranieri PJ, Trillo R, Landesman Y, Senapedis W, McCauley D, Shacham S, Kauffman M, Maris JM, Attiyeh EF. Abstract 501: Inhibition of exportin 1 (XPO1) by selinexor (KPT-330) synergistically suppresses growth of neuroblastoma in combination with doxorubicin or bromodomain inhibition Cancer Research. 75: 501-501. DOI: 10.1158/1538-7445.Am2015-501  0.412
2015 Schonbach M, Danesh A, Bruce J, Woodburn T, Davidsen T, Hermida L, Gesuwan P, Auvil JG, Hampton O, Wheeler D, Gastier-Foster J, Smith M, Gerhard D, Maris JM, Reynolds P, et al. Abstract 484: Fidelity of subclonal representation in human neuroblastoma-derived cell line and patient-derived xenograft models: A report from the NCI-TARGET project Cancer Research. 75: 484-484. DOI: 10.1158/1538-7445.Am2015-484  0.376
2015 Conkrite K, Ferraro N, McDaniel L, Oldridge DA, Attiyeh E, Asgharzadeh S, Diamond M, Auvil JG, Davidsen T, Smith M, London WB, Seeger R, Khan J, Gerhard DS, Maris JM, et al. Abstract 475: Identification of SHANK2 as a tumor suppressor disrupted by recurrent somatic structural variation (SV) in neuroblastoma Cancer Research. 75: 475-475. DOI: 10.1158/1538-7445.Am2015-475  0.439
2015 Schnepp RW, Khurana P, Attiyeh EF, Chodosh S, Raman P, Oldridge DA, Gagliardi ME, Conkrite K, Asgharzadeh S, Seeger RC, Madison B, Rustgi A, Maris JM, Diskin SJ. Abstract 4734: A LIN28B/RAN/AURKA signaling network promotes neuroblastoma tumorigenesis Cancer Research. 75: 4734-4734. DOI: 10.1158/1538-7445.Am2015-4734  0.392
2015 Rader J, Raman P, Hart L, Russell M, Cole KA, Maris JM. Abstract 4305: NMI as a biomarker of response to CDK4/6 inhibition in a preclinical model of neuroblastoma Cancer Research. 75: 4305-4305. DOI: 10.1158/1538-7445.Am2015-4305  0.35
2015 Hart LS, Chen L, Batra V, Tsang M, Raman P, Caponigro G, Krupa S, Boehm M, Peters M, Maris JM. Abstract 3494: Combined MEK1/2 and PI3K inhibition induces synergistic caspase-dependent apoptosis in neuroblastoma Cancer Research. 75: 3494-3494. DOI: 10.1158/1538-7445.Am2015-3494  0.396
2015 Huang M, McHenry LK, Miller ML, Kim GE, Moriarity BS, Miyaoka Y, Bronner ME, Largaespada DA, Conklin BR, Ji HP, Maris JM, Matthay KK, Weiss WA. Abstract 3230: Human stem cell-based model of MYCN-driven neuroblastoma Cancer Research. 75: 3230-3230. DOI: 10.1158/1538-7445.Am2015-3230  0.381
2015 Sotillo E, Barrett D, Bagashev A, Black K, Lanauze C, Oldridge D, Sussman R, Harrington C, Chung EY, Hofmann TJ, Maude SL, Martinez NM, Raman P, Ruella M, Allman D, ... ... Maris J, et al. Abstract 3143: Alternative splicing of CD19 mRNA in leukemias escaping CART-19 immunotherapy eliminates the cognate epitope and contributes to treatment failure Cancer Research. 75: 3143-3143. DOI: 10.1158/1538-7445.Am2015-3143  0.584
2015 Baskar S, Shivaprasad N, Zhu Z, Dimitrov D, Sigrist M, Sorensen P, Yohe M, Shern J, Maris J, Mackall C, Khan J. Abstract 2488: FGFR4 as a potential therapeutic target for monoclonal antibody based intervention in rhabdomyosarcoma Cancer Research. 75: 2488-2488. DOI: 10.1158/1538-7445.Am2015-2488  0.354
2015 Sussman RT, Huang K, Raman P, Maris JM. Abstract 1712: CAMKV as an immunotherapy target in MYCN-amplified neuroblastoma Cancer Research. 75: 1712-1712. DOI: 10.1158/1538-7445.Am2015-1712  0.421
2015 Murphy B, Yin H, Maris JM, Kolb AE, Gorlick R, Reynolds PC, Kang M, Keir ST, Kurmasheva R, Dvorchik I, Wu J, Billups C, Smith MA, Houghton PJ. Abstract 1617: Analysis of single mouse tumor response results from the Pediatric Preclinical Testing Program (PPTP) Cancer Research. 75: 1617-1617. DOI: 10.1158/1538-7445.Am2015-1617  0.387
2015 Smith MA, Lock R, Carol H, Maris JM, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ. Abstract 1616: Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program Cancer Research. 75: 1616-1616. DOI: 10.1158/1538-7445.Am2015-1616  0.419
2015 Smith MA, Kang M, Reynolds PC, Lock RB, Carol H, Gorlick R, Kolb AE, Maris JM, Keir ST, Billups CA, Kurmasheva R, Houghton PJ. Abstract 1615: Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP) Cancer Research. 75: 1615-1615. DOI: 10.1158/1538-7445.Am2015-1615  0.409
2015 Batra V, Ranieri P, Makvandi M, Tsang M, Hou C, Li Y, Vaidyanathan G, Pryma DA, Maris JM. Abstract 1610: Development of meta-[211At]astatobenzylguanidine ([211At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma Cancer Research. 75: 1610-1610. DOI: 10.1158/1538-7445.Am2015-1610  0.396
2015 Russell MR, Penikis A, Oldridge D, Alvarez-Dominguez JR, McDaniel L, Diamond M, Padovan O, Raman P, Li Y, Wei J, Zhang S, Gnanachandran J, Seeger R, Asgharzadeh S, Khan J, ... ... Maris J, et al. Abstract 144: CASC15 is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus Cancer Research. 75: 144-144. DOI: 10.1158/1538-7445.Am2015-144  0.396
2014 Capasso M, Diskin S, Cimmino F, Acierno G, Totaro F, Petrosino G, Pezone L, Diamond M, McDaniel L, Hakonarson H, Iolascon A, Devoto M, Maris JM. Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Research. 74: 6913-24. PMID 25312269 DOI: 10.1158/0008-5472.Can-14-0431  0.336
2014 Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 61: 1972-9. PMID 25131802 DOI: 10.1002/Pbc.25175  0.407
2014 Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 61: 1493-6. PMID 24664981 DOI: 10.1002/Pbc.25026  0.396
2014 Diskin SJ, Capasso M, Diamond M, Oldridge DA, Conkrite K, Bosse KR, Russell MR, Iolascon A, Hakonarson H, Devoto M, Maris JM. Rare variants in TP53 and susceptibility to neuroblastoma. Journal of the National Cancer Institute. 106: dju047. PMID 24634504 DOI: 10.1093/Jnci/Dju047  0.304
2014 Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 61: 1486-9. PMID 24623675 DOI: 10.1002/Pbc.24989  0.34
2014 Murakami-Tonami Y, Kishida S, Takeuchi I, Katou Y, Maris JM, Ichikawa H, Kondo Y, Sekido Y, Shirahige K, Murakami H, Kadomatsu K. Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. Cell Cycle (Georgetown, Tex.). 13: 1115-31. PMID 24553121 DOI: 10.4161/Cc.27983  0.347
2014 Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clinical Pharmacology and Therapeutics. 95: 644-52. PMID 24549002 DOI: 10.1038/Clpt.2014.37  0.335
2014 Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatric Blood & Cancer. 61: 990-6. PMID 24347462 DOI: 10.1002/Pbc.24900  0.303
2014 Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, et al. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 61: 245-52. PMID 24038993 DOI: 10.1002/Pbc.24724  0.406
2014 Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MA. Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 61: 380-2. PMID 24019233 DOI: 10.1002/Pbc.24756  0.363
2014 Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 61: 158-64. PMID 23956067 DOI: 10.1002/Pbc.24616  0.423
2014 Ozkaynak MF, Gilman AL, Yu AL, London WB, Sondel PM, Smith MA, Seeger R, Reynolds CP, Maris JM, Park JR. A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. Journal of Clinical Oncology. 32: 10044-10044. DOI: 10.1200/Jco.2014.32.15_Suppl.10044  0.302
2014 Hart LS, Batra V, Raman P, Gagliardi M, Rader J, Chen L, Fritsch C, Caponigro G, Peters M, Boehm M, Maris JM. Abstract B82: MEK 1/2 inhibition and biomarkers of response in preclinical models of neuroblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B82  0.394
2014 Schnepp R, Hart L, Raman P, Danielson L, Gagliardi M, Kinsey R, Wyce A, Barbash O, Tummino P, Chesler L, Maris J. Abstract B75: Defining the antitumor activity and sensitivity profiles of BET inhibitors in neuroblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B75  0.406
2014 Batra V, Chacko A, Gagliardi M, Hou C, Mikitsh JL, Freifelder RH, Kachur A, LeGeyt BC, Schmitz A, Toto L, Vaidyanathan G, Zalutsky MR, Matthay KK, Weiss WA, Gustafson WC, ... ... Maris JM, et al. Abstract B48: Preclinical development of meta-[211At] astatobenzylguanidine ([211At] MABG) targeted radiotherapy for neuroblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B48  0.395
2014 Wang LL, Teshiba R, He L, Naranjo A, London WB, Gastier-Foster JM, Seeger RC, Cohn SL, Maris JM, Park JR, Hogarty MD, Shimada H. Abstract B40: MYCN/MYC protein expression in high-MKI (Mitosis-Karyorrhexis Index) neuroblastomas: A report from the Children's Oncology Group Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B40  0.342
2014 Attiyeh EF, McKeon-Fish A, Trillo R, Landesman Y, Senapedis W, McCauley D, Kashyap T, Shacham S, Kauffman M, Maris JM. Abstract B36: Inhibition of Exportin 1 (XPO1) potently suppresses growth of human neuroblastoma cell lines Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B36  0.423
2014 Ali SM, Hawryluk MJ, Wang K, Chmielecki J, Palmer GA, Garcia L, White E, Yelensky R, Stephens PJ, Ross JS, Maris JM, Miller VA. Abstract A28: Clinical next-generation sequencing (NGS) reveals genomic alterations (GAs) to guide targeted therapy in advanced neuroblastoma patients Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A28  0.364
2014 Oldridge DA, Wood A, Winter C, Diamond M, Crimmins I, Zhang S, Wei J, Khan J, Capasso M, Rahman N, Diskin SJ, Maris JM. Abstract A27: A noncoding polymorphism in a GATA-containing enhancer element drives the association of LMO1 with neuroblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A27  0.349
2014 Baskar S, Zhu Z, Labitigan RL, Ovanesian M, Orentas RJ, Li SQ, Marielle YE, Shern J, Dimitrov DS, Maris J, Mackall C, Javed K. Abstract 652: Development and characterization of anti-FGFR4 monoclonal antibodies as therapeutic agents for human rhabdomyosarcoma Cancer Research. 74: 652-652. DOI: 10.1158/1538-7445.Am2014-652  0.383
2014 Russell MR, Penikis A, Oldridge D, Diamond M, Diskin S, Maris J, Cole K. Abstract 5237: The long intergenic noncoding RNA LINC00340 is a neuroblastoma susceptibility gene Cancer Research. 74: 5237-5237. DOI: 10.1158/1538-7445.Am2014-5237  0.38
2014 Wei JS, Patidar R, Shern J, Zhang S, Pugh T, Diskin SJ, Sindiri S, Song YK, Liao H, Wen X, Wang J, Skapek SX, Anderson JR, Barr FG, Seeger RC, ... Maris JM, et al. Abstract 5081: Systematic identification of germline mutations in rhabdomyosarcoma and neuroblastoma using massively paralleled sequencing Cancer Research. 74: 5081-5081. DOI: 10.1158/1538-7445.Am2014-5081  0.376
2014 Smith M, Kang M, Reynolds P, Gorlick R, Kolb A, Maris J, Lock R, Carol H, Keir S, Billups C, Kurmasheva R, Houghton P. Abstract 3969: Pediatric preclinical testing program (PPTP) evaluation of BMN 673, an inhibitor of poly-adp ribose polymerase (PARP), with temozolomide (TMZ) Cancer Research. 74: 3969-3969. DOI: 10.1158/1538-7445.Am2014-3969  0.393
2014 Altman BJ, Hsieh A, Gouw AM, Stine ZE, Venkataraman A, Bellovin DI, Diskin SJ, Lu W, Zhang S, Felsher DW, Maris JM, Lazar MA, Rabinowitz JD, Hogenesch JB, Dang CV. Abstract 2953: Rev-erbα modulates Myc-driven cancer cell growth and altered metabolism Cancer Research. 74: 2953-2953. DOI: 10.1158/1538-7445.Am2014-2953  0.325
2014 Hsieh A, Altman B, Stine Z, Gouw A, Venkataraman A, Li B, Goraksha-Hicks P, Diskin S, Bellovin D, Celeste Simon M, Rathmell J, Lazar M, Maris J, Felsher D, Hogenesch J, et al. TM-06 * MYC AND MYCN DISRUPTION OF THE MOLECULAR CLOCK IN CANCER CELLS Neuro-Oncology. 16: v214-v214. DOI: 10.1093/Neuonc/Nou278.6  0.327
2014 Houghton P, Lock R, Carol H, Gorlick R, Kolb A, Maris J, Keir S, Wu J, Kang M, Reynolds P, Kurmasheva R, Smith M. 412 The Pediatric Preclinical Testing Program (PPTP): Analysis of the first 10 years in vivo testing European Journal of Cancer. 50: 131-132. DOI: 10.1016/S0959-8049(14)70538-6  0.328
2013 Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, ... ... Maris JM, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6173-82. PMID 24045179 DOI: 10.1158/1078-0432.Ccr-13-1675  0.312
2013 Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer. 119: 3718-26. PMID 23901000 DOI: 10.1002/Cncr.28251  0.381
2013 Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatric Blood & Cancer. 60: 1860-7. PMID 23798344 DOI: 10.1002/Pbc.24647  0.352
2013 Hill-Kayser C, Tochner Z, Both S, Lustig R, Reilly A, Balamuth N, Womer R, Maris J, Grupp S, Bagatell R. Proton versus photon radiation therapy for patients with high-risk neuroblastoma: the need for a customized approach. Pediatric Blood & Cancer. 60: 1606-11. PMID 23737005 DOI: 10.1002/Pbc.24606  0.301
2013 Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. The Lancet. Oncology. 14: 472-80. PMID 23598171 DOI: 10.1016/S1470-2045(13)70095-0  0.341
2013 Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 60: 1325-32. PMID 23553917 DOI: 10.1002/Pbc.24517  0.403
2013 Schnepp RW, Maris JM. Targeting MYCN: a good BET for improving neuroblastoma therapy? Cancer Discovery. 3: 255-7. PMID 23475876 DOI: 10.1158/2159-8290.Cd-13-0018  0.324
2013 Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 541-8. PMID 23440556 DOI: 10.2967/Jnumed.112.112334  0.335
2013 Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatric Blood & Cancer. 60: 783-90. PMID 23335050 DOI: 10.1002/Pbc.24368  0.33
2013 Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, ... ... Maris JM, et al. The genetic landscape of high-risk neuroblastoma. Nature Genetics. 45: 279-84. PMID 23334666 DOI: 10.1038/Ng.2529  0.343
2013 Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplantation. 48: 947-52. PMID 23334272 DOI: 10.1038/Bmt.2012.276  0.314
2013 Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 60: E42-5. PMID 23303741 DOI: 10.1002/Pbc.24451  0.374
2013 Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Mattay KM, Hogarty M. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatric Blood & Cancer. 60: 985-93. PMID 23255319 DOI: 10.1002/Pbc.24433  0.363
2013 Gamazon ER, Pinto N, Konkashbaev A, Im HK, Diskin SJ, London WB, Maris JM, Dolan ME, Cox NJ, Cohn SL. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. Journal of the National Cancer Institute. 105: 302-9. PMID 23243203 DOI: 10.1093/Jnci/Djs503  0.351
2013 Capasso M, Diskin SJ, Totaro F, Longo L, De Mariano M, Russo R, Cimmino F, Hakonarson H, Tonini GP, Devoto M, Maris JM, Iolascon A. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis. 34: 605-11. PMID 23222812 DOI: 10.1093/Carcin/Bgs380  0.319
2013 Russell MR, Levin K, Rader J, Belcastro L, Li Y, Martinez D, Pawel B, Shumway SD, Maris JM, Cole KA. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Research. 73: 776-84. PMID 23135916 DOI: 10.1158/0008-5472.Can-12-2669  0.391
2013 Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MA. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 60: 791-8. PMID 23002019 DOI: 10.1002/Pbc.24301  0.376
2013 Mayes PA, Degenhardt YY, Wood A, Toporovskya Y, Diskin SJ, Haglund E, Moy C, Wooster R, Maris JM. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. International Journal of Cancer. Journal International Du Cancer. 132: E149-57. PMID 22948716 DOI: 10.1002/Ijc.27781  0.355
2013 Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 60: 633-41. PMID 22753001 DOI: 10.1002/Pbc.24235  0.346
2013 Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, et al. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatric Blood & Cancer. 60: 363-70. PMID 22744966 DOI: 10.1002/Pbc.24238  0.367
2013 Houghton P, Kang M, Reynolds P, Gorlick R, Kolb A, Maris J, Keir S, Carol H, Lock R, Billups C, Kurmasheva R, Landesman Y, Shacham S, Kauffman M, Smith MA. Abstract LB-354: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the XPO1/CRM1 inhibitor KPT-330. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-354  0.431
2013 Smith M, Kang M, Reynolds P, Gorlick R, Kolb A, Maris J, Keir S, Billups C, Kurmasheva R, Houghton P. Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-353  0.428
2013 Pineros VM, Bosse KR, Hart LS, Diskin SJ, Rader J, Maris JM. Abstract 3816: DNA variation at BARD1 predicts response to aurora kinase inhibition in neuroblastoma. Cancer Research. 73: 3816-3816. DOI: 10.1158/1538-7445.Am2013-3816  0.39
2013 Diskin SJ, Capasso M, Diamond M, Bosse K, Hakonarson H, Devoto M, Maris JM. Abstract 3811: Rare variants at 16p11.2 and withinTP53influence neuroblastoma susceptibility. Cancer Research. 73: 3811-3811. DOI: 10.1158/1538-7445.Am2013-3811  0.317
2013 Wood AC, Pugh TJ, Morozova O, Koster J, Molenaar JJ, Pineros V, Bosse KR, Perin JC, Diskin S, Diamond MA, Marra M, Meyerson M, Versteeg R, Maris JM. Abstract 3804: Rare DNA variants are enriched at the BARD1 locus and likely influence neuroblastoma susceptibility. Cancer Research. 73: 3804-3804. DOI: 10.1158/1538-7445.Am2013-3804  0.342
2013 Zhu S, Wood A, He S, Stanton R, Guo F, Maris J, Look AT. Abstract 356: Role of the LMO1 oncogene in neuroblastoma pathogenesis. Cancer Research. 73: 356-356. DOI: 10.1158/1538-7445.Am2013-356  0.387
2013 Carpenter EL, Rader J, Krytska K, Ruden J, Rappaport E, Mosse Y, Fontana F, Banzi M, Medoro G, Manaresi N, O'Dwyer P, Maris J. Abstract 3512: Dielectrophoretic capture and genetic analysis of individual disseminated solid tumor cells. Cancer Research. 73: 3512-3512. DOI: 10.1158/1538-7445.Am2013-3512  0.392
2013 Woodburn T, Hall HA, White K, Calderon R, Blaydes R, Farooqi A, Hogarty M, Mosse Y, Maris J, Erdreich-Epstein A, Miller B, Reynolds CP. Abstract 2786: Establishing validated pediatric cancer cell lines and direct xenografts from post-mortem samples. Cancer Research. 73: 2786-2786. DOI: 10.1158/1538-7445.Am2013-2786  0.363
2013 Houghton P, Kang MH, Reynolds P, Lock R, Carol H, Gorlick R, Kolb A, Maris J, Keir S, Billups C, Kurmasheva R, Smith M. Abstract 2758: Pediatric preclinical testing program (PPTP) stage 1 evaluation of MLN0128, a potent TOR kinase inhibitor. Cancer Research. 73: 2758-2758. DOI: 10.1158/1538-7445.Am2013-2758  0.42
2013 Attiyeh EF, McKeon-Fish A, Landesman Y, Senapedis W, McCauley D, Kashyap T, Shacham S, Kauffman M, Maris JM. Abstract 2756: Targeted inhibition of Chromosomal Maintenance Region Protein (CRM1) potently suppresses growth of human neuroblastoma cell line models. Cancer Research. 73: 2756-2756. DOI: 10.1158/1538-7445.Am2013-2756  0.432
2013 Smith M, Kang M, Reynolds P, Gorlick R, Kolb A, Maris J, Keir S, Billups C, Kurmasheva R, Houghton P, Collins J. Abstract 2755: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of NSC750854, a sulfamated purine analog with a distinctive anticancer activity profile. Cancer Research. 73: 2755-2755. DOI: 10.1158/1538-7445.Am2013-2755  0.424
2013 Houghton PJ, Kang M, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA, Kurmasheva RT, Smith MA. Abstract 2754: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the antimicrotubule agents cabazitaxel and docetaxel. Cancer Research. 73: 2754-2754. DOI: 10.1158/1538-7445.Am2013-2754  0.349
2013 Rader J, Hart L, Russell M, Nakazawa M, Belcastro L, Martinez D, Carpenter E, Kim S, Parasuraman S, Caponigro G, Schnepp R, Wood A, Pawel B, Watson D, Warren P, ... ... Maris J, et al. Abstract 2744: CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas. Cancer Research. 73: 2744-2744. DOI: 10.1158/1538-7445.Am2013-2744  0.426
2013 Smith M, Kang M, Reynolds P, Gorlick R, Kolb A, Maris J, Lock R, Carol H, Keir S, Billups C, Kurmasheva R, Houghton P. Abstract C206: Pediatric Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C206  0.402
2012 Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, Mayes PA, Wise DR, Thompson CB, Maris JM, Hogarty MD, Simon MC. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 22: 631-44. PMID 23153536 DOI: 10.1016/J.Ccr.2012.09.021  0.315
2012 Dubois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A, London WB, Kreissman S, Baker D, Attiyeh E, Hogarty MD, ... Maris JM, et al. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. International Journal of Molecular Imaging. 2012: 250834. PMID 23050139 DOI: 10.1155/2012/250834  0.328
2012 Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, Hou C, Diamond M, Carpenter EL, Winter C, Lee H, Jagannathan J, Latorre V, Iolascon A, Hakonarson H, Devoto M, ... Maris JM, et al. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nature Genetics. 44: 1126-30. PMID 22941191 DOI: 10.1038/Ng.2387  0.334
2012 Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, et al. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1155-63. PMID 22700000 DOI: 10.2967/Jnumed.111.098624  0.327
2012 Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2423-8. PMID 22427348 DOI: 10.1158/1078-0432.Ccr-11-1409  0.392
2012 DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2679-86. PMID 22421195 DOI: 10.1158/1078-0432.Ccr-11-3201  0.302
2012 Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, Nguyen le B, Jagannathan J, Laquaglia M, Winter C, Diamond M, Hou C, Attiyeh EF, Mosse YP, Pineros V, ... ... Maris JM, et al. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Research. 72: 2068-78. PMID 22350409 DOI: 10.1158/0008-5472.Can-11-3703  0.39
2012 Hogarty MD, Maris JM. PI3King on MYCN to improve neuroblastoma therapeutics. Cancer Cell. 21: 145-7. PMID 22340587 DOI: 10.1016/J.Ccr.2012.01.018  0.342
2012 Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 1266-74. PMID 22315240 DOI: 10.1002/Pbc.24073  0.392
2012 Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 749-52. PMID 22052829 DOI: 10.1002/Pbc.23364  0.382
2012 Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatric Blood & Cancer. 58: 815-8. PMID 22052798 DOI: 10.1002/Pbc.23290  0.378
2012 Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 246-53. PMID 22012946 DOI: 10.1002/Pbc.23357  0.391
2012 Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 329-32. PMID 21922647 DOI: 10.1002/Pbc.23319  0.397
2012 Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 58: 636-9. PMID 21681929 DOI: 10.1002/Pbc.23167  0.398
2012 Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, Wozniak AW, Smith MA, Houghton PJ. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatric Blood & Cancer. 58: 729-35. PMID 21630428 DOI: 10.1002/Pbc.23157  0.354
2012 Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatric Blood & Cancer. 58: 916-23. PMID 21584937 DOI: 10.1002/Pbc.23176  0.412
2012 Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 58: 200-9. PMID 21548007 DOI: 10.1002/Pbc.23016  0.369
2012 Morton CL, Maris JM, Keir ST, Gorlick R, Kolb EA, Billups CA, Wu J, Smith MA, Houghton PJ. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatric Blood & Cancer. 58: 566-71. PMID 21538824 DOI: 10.1002/Pbc.23159  0.307
2012 Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 185-8. PMID 21538821 DOI: 10.1002/Pbc.23154  0.387
2012 Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 58: 191-9. PMID 21337679 DOI: 10.1002/Pbc.22935  0.405
2012 Meany HJ, Attiyeh EF, Naranjo A, Twist C, London WB, Villablanca J, Schmidt ML, Baker D, Strother DR, Shimada H, Matthay KK, Cohn SL, Maris JM, Park JR. Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children’s Oncology Group trials P9641 and A3961. Journal of Clinical Oncology. 30: 9533-9533. DOI: 10.1200/Jco.2012.30.15_Suppl.9533  0.343
2012 Maris JM. Abstract SY25-03: Host and tumor genetic architecture influence clinically relevant oncogenic pathways in neuroblastoma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy25-03  0.377
2012 Sotillo-Piñeiro E, Xu L, Nguyen L, Laver T, Attiyeh E, Cole K, Diskin S, Maris J, Thomas-Tikhonenko A. Abstract LB-475: 3′UTR polymorphisms affect expression and activity of IGF1R, a therapeutic target in pediatric neuroblastoma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-475  0.64
2012 Carol H, Lock R, Maris J, Keir S, Gorlick R, Kolb A, Kang M, Reynolds P, Wu J, Kurmasheva R, Houghton P, Smith M. Abstract LB-318: Pediatric Preclinical Testing Program (PPTP) evaluation of the JAK inhibitor AZD1480 Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-318  0.419
2012 Smith M, Keir S, Maris J, Kolb A, Reynolds P, Kang M, Carol H, Lock R, Gorlick R, Kurmasheva R, Billups C, Houghton P. Abstract LB-317: Pediatric Preclinical Testing Program (PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK) inhibitor Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-317  0.427
2012 Carlisle AJ, Pawal B, Carlisle R, Jagannathan J, Martinez D, Zhao H, Wang Q, Cole K, Lyttle CA, Nguyen N, Maris JM. Abstract 5566: Elevated CXCR4 expression is clinically correlated with advanced stage neuroblastoma: examination of its role as a possible therapeutic target Cancer Research. 72: 5566-5566. DOI: 10.1158/1538-7445.Am2012-5566  0.395
2012 Diskin SJ, Capasso M, Latorre V, Schnepp R, Attiyeh EF, Diamond M, Hou C, Carpenter EL, Lee H, Cole KA, Asgharzadeh S, Hakonarson H, Devoto M, Maris JM. Abstract 4871: New neuroblastoma susceptibility loci at 6q21 withinHACE1andLIN28B Cancer Research. 72: 4871-4871. DOI: 10.1158/1538-7445.Am2012-4871  0.389
2012 Pinto N, Gamazon ER, Im HK, Konkashbaev A, Cox NJ, Dolan ME, Diskin SJ, London WB, Maris JM, Cohn SL. Abstract 2486: African ancestry is associated with high-risk disease and event-free survival in children with neuroblastoma Cancer Research. 72: 2486-2486. DOI: 10.1158/1538-7445.Am2012-2486  0.33
2012 Russell M, Levin K, Rader J, Toniatti C, Maris JM, Cole KA. Abstract 1436: Therapeutic targeting of the DNA damage mediators CHK1 and Wee1 in neuroblastoma Cancer Research. 72: 1436-1436. DOI: 10.1158/1538-7445.Am2012-1436  0.411
2011 Weiser D, Laudenslager M, Rappaport E, Carpenter E, Attiyeh EF, Diskin S, London WB, Maris JM, Mosse YP. Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9514. PMID 28019813 DOI: 10.1200/Jco.2011.29.15_Suppl.9514  0.312
2011 Matthay KK, Weiss BD, Villablanca J, Maris JM, Yanik GA, Groshen SG, Jackson H, Hawkins R, Goodarzian F, Panigrahy A, DuBois SG, Stubbs J, Towbin A, Barrett JA, LaFrance ND, et al. Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9512. PMID 28019801 DOI: 10.1200/Jco.2011.29.15_Suppl.9512  0.352
2011 Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, Christensen JG, Maris JM, Lemmon MA, Mossé YP. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Science Translational Medicine. 3: 108ra114. PMID 22072639 DOI: 10.1126/Scitranslmed.3002950  0.339
2011 Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 57: 443-53. PMID 21744473 DOI: 10.1002/Pbc.22921  0.363
2011 Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM, Mosse YP. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatric Blood & Cancer. 57: 1124-9. PMID 21495159 DOI: 10.1002/Pbc.23062  0.313
2011 Abel F, Dalevi D, Nethander M, Jörnsten R, Preter KD, Vermeulen J, Stallings RL, Kogner P, Maris J, Nilsson S. A 6-gene signature identifies four molecular subgroups of neuroblastoma Cancer Cell International. 11: 9-9. PMID 21492432 DOI: 10.1186/1475-2867-11-9  0.31
2011 Nguyen le B, Diskin SJ, Capasso M, Wang K, Diamond MA, Glessner J, Kim C, Attiyeh EF, Mosse YP, Cole K, Iolascon A, Devoto M, Hakonarson H, Li HK, Maris JM. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. Plos Genetics. 7: e1002026. PMID 21436895 DOI: 10.1371/Journal.Pgen.1002026  0.352
2011 Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ. Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatric Blood & Cancer. 57: 606-11. PMID 21360651 DOI: 10.1002/Pbc.22877  0.401
2011 Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 57: 268-74. PMID 21360650 DOI: 10.1002/Pbc.22797  0.414
2011 Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 56: 595-603. PMID 21298745 DOI: 10.1002/Pbc.22741  0.406
2011 Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, Laudenslager M, Wood AC, Mayes PA, Jagannathan J, Winter C, ... ... Maris JM, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America. 108: 3336-41. PMID 21289283 DOI: 10.1073/Pnas.1012351108  0.39
2011 Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L, Bliskovsky V, Mock B, Ried T, London WB, Maris J, Khan J, Thiele CJ. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell Death and Differentiation. 18: 1174-83. PMID 21252912 DOI: 10.1038/Cdd.2010.187  0.385
2011 Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, Schnepp RW, Diamond M, Bosse K, Mayes PA, Glessner J, Kim C, Frackelton E, Garris M, Wang Q, ... ... Maris JM, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 469: 216-20. PMID 21124317 DOI: 10.1038/Nature09609  0.374
2011 Morozova O, Birol I, Corbett R, Mungall K, Attiyeh EF, Asgharzadeh S, Zhao Y, Moore RA, Hirst M, Jones S, Hogarty MD, Diskin S, Mosse YP, Diamond M, Sposto R, ... ... Maris JM, et al. Abstract 926: Whole genome and transcriptome sequencing defines the spectrum of somatic changes in high-risk neuroblastoma Cancer Research. 71: 926-926. DOI: 10.1158/1538-7445.Am2011-926  0.357
2011 Carpenter EL, Haglund EA, Chow AK, Christensen JG, Maris JM, Mosse YP. Abstract 742: Mechanisms of resistance to small molecule inhibition of anaplastic lymphoma kinase in human neuroblastoma Cancer Research. 71: 742-742. DOI: 10.1158/1538-7445.Am2011-742  0.347
2011 Carol H, Lock RB, Maris JM, Keir ST, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Morton CL, Smith PG, Thomas M, McDonald A, Houghton PJ, Smith MA. Abstract 740: Pediatric Preclinical Testing Program (PPTP) evaluation of the NEDD8-activating enzyme (NAE) inhibitor MLN4924 Cancer Research. 71: 740-740. DOI: 10.1158/1538-7445.Am2011-740  0.419
2011 Houghton PJ, Lock RB, Carol H, Morton CL, Gorlick R, Kolb EA, Kier ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Smith MA. Abstract 5358: Pediatric preclinical testing program (PPTP) evaluation of the non-camptothecin topoisomerase 1 targeted agent Genz644282 Cancer Research. 71: 5358-5358. DOI: 10.1158/1538-7445.Am2011-5358  0.409
2011 Russell MR, Cole KA, Maris JM. Abstract 4758: Inhibition of checkpoint kinase 1 (Chk1) as a potential therapeutic for pediatric neuroblastoma Cancer Research. 71: 4758-4758. DOI: 10.1158/1538-7445.Am2011-4758  0.417
2011 Pugh TJ, Lawrence M, Sougnez C, Getz G, Attiyeh E, Hogarty M, Diskin S, Yael M, Diamond M, Asgharzadeh S, Sposto R, Wei JS, Badgett T, London WB, Gastier-Foster J, ... ... Maris JM, et al. Abstract 4756: Exome sequencing of 81 neuroblastomas identifies a wide diversity of somatic mutation Cancer Research. 71: 4756-4756. DOI: 10.1158/1538-7445.Am2011-4756  0.39
2011 Bresler SC, Wood A, Haglund E, Christensen J, Maris JM, Lemmon MA, Mosse YP. Abstract 4685: Mechanistic guidance of ALK inhibition for the treatment of neuroblastoma Cancer Research. 71: 4685-4685. DOI: 10.1158/1538-7445.Am2011-4685  0.356
2011 Carpenter EL, Haglund EA, Chow AK, Wood AC, Belcastro LT, Christensen JG, Vigny M, Maris JM, Lemmon MA, Mosse YP. Abstract 4563: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma Cancer Research. 71: 4563-4563. DOI: 10.1158/1538-7445.Am2011-4563  0.354
2011 Reynolds CP, Kang MH, Carol H, Lock RB, Gorlick R, Kolb EA, Alexander D, Kurmasheva RT, Keir ST, Maris JM, Wu J, Houghton PJ, Smith MA. Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408). Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C106  0.405
2011 Houghton PJ, Maris JM, Keir ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Kurmasheva RT, Whiteman KR, Smith MA. Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C105  0.397
2011 Smith MA, Kang MH, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ. Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C103  0.43
2011 Pinto NR, Gamazon ER, Konkashbaev A, Cox NJ, Dolan ME, Diskin SJ, London WB, Devoto M, Maris JM, Cohn SL. Abstract A46: Genomic ancestry is associated with risk group and survival in children with neuroblastoma Cancer Epidemiology, Biomarkers & Prevention. 20. DOI: 10.1158/1055-9965.Disp-11-A46  0.331
2010 Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, Maris JM, Simon MC. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Research. 70: 10351-61. PMID 20961996 DOI: 10.1158/0008-5472.Can-10-0740  0.335
2010 Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, ... Maris JM, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Research. 70: 9554-61. PMID 20935224 DOI: 10.1158/0008-5472.Can-10-2211  0.301
2010 Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. The New England Journal of Medicine. 363: 1313-23. PMID 20879880 DOI: 10.1056/Nejmoa1001527  0.358
2010 Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 55: 668-77. PMID 20806365 DOI: 10.1002/Pbc.22576  0.394
2010 Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 55: 1329-37. PMID 20740623 DOI: 10.1002/Pbc.22710  0.401
2010 Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 55: 1126-33. PMID 20672370 DOI: 10.1002/Pbc.22712  0.403
2010 Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 55: 295-303. PMID 20582972 DOI: 10.1002/Pbc.22535  0.405
2010 Balamuth NJ, Wood A, Wang Q, Jagannathan J, Mayes P, Zhang Z, Chen Z, Rappaport E, Courtright J, Pawel B, Weber B, Wooster R, Sekyere EO, Marshall GM, Maris JM. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Research. 70: 2749-58. PMID 20233875 DOI: 10.1158/0008-5472.Can-09-3844  0.415
2010 Iyer R, Evans AE, Qi X, Ho R, Minturn JE, Zhao H, Balamuth N, Maris JM, Brodeur GM. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1478-85. PMID 20179224 DOI: 10.1158/1078-0432.Ccr-09-1531  0.388
2010 Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 54: 921-6. PMID 20166202 DOI: 10.1002/Pbc.22367  0.34
2010 Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Molecular Cancer Therapeutics. 9: 101-12. PMID 20053767 DOI: 10.1158/1535-7163.Mct-09-0952  0.371
2010 Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, Medina D, Xiong H, Krivoshik A, Widemann B, Adamson PC, Balis FM. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemotherapy and Pharmacology. 66: 737-43. PMID 20044751 DOI: 10.1007/S00280-009-1218-Z  0.322
2010 Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Watkins A, Smith MA, Lock RB. Initial testing of topotecan by the pediatric preclinical testing program. Pediatric Blood & Cancer. 54: 707-15. PMID 20017204 DOI: 10.1002/Pbc.22352  0.402
2010 Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 54: 307-10. PMID 19856388 DOI: 10.1002/Pbc.22188  0.368
2010 Meany HJ, Sackett DL, Maris JM, Ward Y, Krivoshik A, Cohn SL, Steinberg SM, Balis FM, Fox E. Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. Pediatric Blood & Cancer. 54: 47-54. PMID 19731320 DOI: 10.1002/Pbc.22267  0.396
2010 Minturn JE, Villablanca J, Yanik GA, Park JR, Groshen SG, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM. Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium study. Journal of Clinical Oncology. 28: 9532-9532. DOI: 10.1200/Jco.2010.28.15_Suppl.9532  0.336
2010 Smith MA, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang M, Reynolds CP, Morton CL, Houghton PJ. Abstract 5266: Pediatric Preclinical Testing Program (PPTP) evaluation of the CDK inhibitor SCH 727965 Cancer Research. 70: 5266-5266. DOI: 10.1158/1538-7445.Am10-5266  0.43
2010 Houghton PJ, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang M, Reynolds CP, Morton CL, Smith MA. Abstract 5265: Pediatric preclinical testing program (PPTP) stage 1 evaluation of BMS-754807 IGF-1 receptor inhibitor Cancer Research. 70: 5265-5265. DOI: 10.1158/1538-7445.Am10-5265  0.407
2010 Cole KA, Huggins J, Laquaglia M, Diskin S, Attiyeh EF, Hulderman C, Han M, Bosse K, Jagannathan J, Mosse YP, Mayes P, Maris JM. Abstract 5263: An RNAi screen of the protein kinome identifiesCHEK1as a therapeutic target in neuroblastoma Cancer Research. 70: 5263-5263. DOI: 10.1158/1538-7445.Am10-5263  0.402
2010 Attiyeh EF, Hogarty MD, Mossé YP, Diskin SJ, Hakonarson H, Asgharzadeh S, Sposto R, London WB, Gastier-Foster JM, Gerhard DS, Smith MA, Zhang J, Khan J, Seeger RC, Maris JM. Abstract 5258: Genomic characterization and targeted resequencing of high-risk neuroblastoma (the neuroblastoma TARGET) Cancer Research. 70: 5258-5258. DOI: 10.1158/1538-7445.Am10-5258  0.345
2010 Norris RE, Minturn JE, Brodeur GM, Maris JM, Adamson PC. Abstract 5257: Preclinical evaluation of lestaurtinib (CEP-701) with the retinoids for neuroblastoma Cancer Research. 70: 5257-5257. DOI: 10.1158/1538-7445.Am10-5257  0.36
2010 Mayes PA, Diskin S, Attiyeh EF, Toporovskaya Y, Maris JM. Abstract 5256: The identification of fatty acid synthase (FASN) as a candidate oncogene and therapeutic target in neuroblastoma Cancer Research. 70: 5256-5256. DOI: 10.1158/1538-7445.Am10-5256  0.406
2010 Diskin SJ, Jagganathan J, Diamond M, Hou C, Wang K, Zhang H, Li H, Mosse YP, Hakonarson H, Maris JM. Abstract 5253: Rare copy number variations (CNVs) influence neuroblastoma susceptibility Cancer Research. 70: 5253-5253. DOI: 10.1158/1538-7445.Am10-5253  0.341
2010 Asgharzadeh S, Ji L, Sposto R, Attiyeh E, Tu Y, Hadjidaniel M, Hogarty MD, London WB, Gastier-Foster J, Wei J, Guo X, Gerhard DS, Smith MA, Khan J, Maris JM, et al. Abstract 5249: Identification of genome-wide alternative splicing events in high-riskMYCNamplified neuroblastomas Cancer Research. 70: 5249-5249. DOI: 10.1158/1538-7445.Am10-5249  0.369
2010 Liu Z, London WB, Maris J, Thiele CJ. Abstract 5015: Hcasz5, CASZ1 gene transcript variant 2 with 5 zinc fingers functions as a tumor suppressor in Neuroblastoma Cancer Research. 70: 5015-5015. DOI: 10.1158/1538-7445.Am10-5015  0.384
2010 Diskin SJ, Bosse K, Mayes PA, LaQuaglia M, Attiyeh EF, Laudenslager M, Mosse YP, Diamond M, Belcastro L, Toporovskaya Y, Norris G, Hou C, Wang K, Zhang H, Kim C, ... ... Maris JM, et al. Abstract 3866: Identification ofNME7as a predisposition locus and candidate oncogene in neuroblastoma Cancer Research. 70: 3866-3866. DOI: 10.1158/1538-7445.Am10-3866  0.417
2009 Carlisle AJ, Lyttle CA, Carlisle RY, Maris JM. CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation. Molecular Cancer. 8: 126-126. PMID 20028517 DOI: 10.1186/1476-4598-8-126  0.376
2009 Mossé YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clinical Cancer Research. 15: 5609-5614. PMID 19737948 DOI: 10.1158/1078-0432.Ccr-08-2762  0.354
2009 Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 53: 594-8. PMID 19554571 DOI: 10.1002/Pbc.21989  0.324
2009 Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, Cole K, Mossé YP, Wood A, Lynch JE, Pecor K, Diamond M, Winter C, Wang K, Kim C, ... ... Maris JM, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 459: 987-91. PMID 19536264 DOI: 10.1038/Nature08035  0.339
2009 Volchenboum SL, Li C, Li S, Attiyeh EF, Reynolds CP, Maris JM, Look AT, George RE. Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Research. 69: 4143-9. PMID 19435921 DOI: 10.1158/0008-5472.Can-08-3112  0.371
2009 Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 53: 505-8. PMID 19418547 DOI: 10.1002/Pbc.21988  0.383
2009 Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA. Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatric Blood & Cancer. 53: 509-12. PMID 19418543 DOI: 10.1002/Pbc.21976  0.378
2009 Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British Journal of Cancer. 100: 1471-82. PMID 19401703 DOI: 10.1038/Sj.Bjc.6605014  0.305
2009 Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1020-5. PMID 19171714 DOI: 10.1200/Jco.2007.15.7628  0.301
2009 Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1290-6. PMID 19171709 DOI: 10.1200/Jco.2008.18.5918  0.311
2009 Attiyeh EF, Diskin SJ, Attiyeh MA, Mossé YP, Hou C, Jackson EM, Kim C, Glessner J, Hakonarson H, Biegel JA, Maris JM. Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome Research. 19: 276-83. PMID 19141597 DOI: 10.1101/Gr.075671.107  0.322
2009 Maris JM. Unholy Matrimony: Aurora A and N-Myc as Malignant Partners in Neuroblastoma Cancer Cell. 15: 5-6. PMID 19111875 DOI: 10.1016/J.Ccr.2008.12.008  0.3
2009 Houghton PJ, Maris JM, Courtright J, Friedman HS, Keir ST, Lock RB, Carol H, Kolb EA, Gorlick R, Kang M, Reynolds CP, Morton CL, Smith MA. Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C57  0.407
2009 Qing G, Mayes P, Pawel B, Martinez D, Maris JM, Simon MC. Abstract C15: Combinatorial regulation of neuroblastoma tumor progression by HIF1α and N‐myc transcriptional factors Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C15  0.396
2008 Kreissman SG, Villablanca JG, Seeger RC, Grupp SA, London WB, Maris JM, Park JR, Cohn SL, Matthay KK, Reynolds CP. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 10011. PMID 27951329 DOI: 10.1200/Jco.2008.26.15_Suppl.10011  0.352
2008 Park JR, London WB, Maris JM, Shimada H, Zhang Y, Matthay KK, Monclair T, Ambros PF, Cohn SL, Pearson A. Prognostic markers for stage 3 neuroblastoma (NB): A report from the International Neuroblastoma Risk Group (INRG) project. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 10009. PMID 27951252 DOI: 10.1200/Jco.2008.26.15_Suppl.10009  0.305
2008 Fredlund E, Ringnér M, Maris JM, Påhlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America. 105: 14094-9. PMID 18780787 DOI: 10.1073/Pnas.0804455105  0.349
2008 Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, ... ... Maris JM, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 455: 930-5. PMID 18724359 DOI: 10.1038/Nature07261  0.329
2008 Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, et al. Molecular characterization of the pediatric preclinical testing panel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4572-83. PMID 18628472 DOI: 10.1158/1078-0432.Ccr-07-5090  0.318
2008 Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. Journal of the National Cancer Institute. 100: 940-9. PMID 18577749 DOI: 10.1093/Jnci/Djn176  0.348
2008 Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, Maris JM. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Molecular Cancer Research : McR. 6: 735-42. PMID 18505919 DOI: 10.1158/1541-7786.Mcr-07-2102  0.312
2008 Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris JM, Look AT, Meyerson M, Peeper DS, et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes & Development. 22: 884-93. PMID 18334619 DOI: 10.1101/Gad.1648608  0.344
2008 Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 51: 42-8. PMID 18293383 DOI: 10.1002/Pbc.21535  0.409
2008 Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 51: 34-41. PMID 18260120 DOI: 10.1002/Pbc.21508  0.375
2008 Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 1190-7. PMID 18260118 DOI: 10.1002/Pbc.21450  0.4
2008 Winter C, Pawel B, Seiser E, Zhao H, Raabe E, Wang Q, Judkins AR, Attiyeh E, Maris JM. Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status. Pediatric Blood & Cancer. 51: 10-6. PMID 18213713 DOI: 10.1002/Pbc.21475  0.336
2008 Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 1181-9. PMID 18085673 DOI: 10.1002/Pbc.21433  0.404
2008 Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 1198-206. PMID 17914733 DOI: 10.1002/Pbc.21368  0.405
2008 Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 799-805. PMID 17635004 DOI: 10.1002/Pbc.21296  0.422
2008 Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 992-1000. PMID 17554786 DOI: 10.1002/Pbc.21263  0.396
2008 Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 581-7. PMID 17457854 DOI: 10.1002/Pbc.21232  0.391
2008 Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 37-45. PMID 17420992 DOI: 10.1002/Pbc.21214  0.369
2007 Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jagannathan J, Bhambhani K, Winter C, Maris JM. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression Genes Chromosomes and Cancer. 46: 936-949. PMID 17647283 DOI: 10.1002/Gcc.20477  0.362
2007 Raabe EH, Laudenslager M, Winter C, Wasserman N, Cole K, LaQuaglia M, Maris DJ, Mosse YP, Maris JM. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene. 27: 469-76. PMID 17637745 DOI: 10.1038/Sj.Onc.1210659  0.363
2007 Peddinti R, Zeine R, Luca D, Seshadri R, Chlenski A, Cole K, Pawel B, Salwen HR, Maris JM, Cohn SL. Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma Clinical Cancer Research. 13: 3499-3506. PMID 17575212 DOI: 10.1158/1078-0432.Ccr-07-0237  0.379
2007 George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JM. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. Plos One. 2: e255. PMID 17327916 DOI: 10.1371/Journal.Pone.0000255  0.303
2007 Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood & Cancer. 49: 928-40. PMID 17066459 DOI: 10.1002/Pbc.21078  0.407
2007 Attiyeh EF, Mosse YP, Diskin S, Hou C, Attiyeh MA, Baker D, Strother D, Schmidt M, London WB, Maris JM. Identification of genomic DNA signatures predicting relapse in low- and intermediate-risk neuroblastoma using a case control design and high-density SNP genotyping: A Children's Oncology Group (COG) study Journal of Clinical Oncology. 25: 9500-9500. DOI: 10.1200/Jco.2007.25.18_Suppl.9500  0.349
2007 Smith MA, Maris JM, Keir ST, Lock RB, Carol H, Gorlick R, Kolb EA, Keshelava N, Reynolds CP, Morton C, Houghton PJ. Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG Journal of Clinical Oncology. 25: 3575-3575. DOI: 10.1200/Jco.2007.25.18_Suppl.3575  0.407
2007 Peddinti R, Zeine R, Luca D, Seshadri R, Chlenski A, Cole K, Pawel B, Salwen H, Maris J, Cohn SL. Prominent vascular endothelial proliferation in clinically aggressive neuroblastoma Journal of Clinical Oncology. 25: 10611-10611. DOI: 10.1200/Jco.2007.25.18_Suppl.10611  0.327
2006 Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers GA, Pinkus JL, Pinkus GS, Maris JM, et al. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5725-34. PMID 17179106 DOI: 10.1200/Jco.2005.05.3314  0.363
2006 Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, Wahl ML. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Molecular Pharmacology. 70: 2108-15. PMID 17000864 DOI: 10.1124/Mol.106.026245  0.33
2006 Diskin SJ, Eck T, Greshock J, Mosse YP, Naylor T, Stoeckert CJ, Weber BL, Maris JM, Grant GR. STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Research. 16: 1149-58. PMID 16899652 DOI: 10.1101/Gr.5076506  0.317
2006 Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, ... ... Maris JM, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Research. 66: 6050-62. PMID 16778177 DOI: 10.1158/0008-5472.Can-05-4618  0.375
2006 Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O'Meara A, Breatnach F. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Research. 66: 3673-3680. PMID 16585193 DOI: 10.1158/0008-5472.Can-05-4154  0.329
2006 Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study Journal of Clinical Oncology. 24: 500-506. PMID 16421427 DOI: 10.1200/Jco.2005.03.6400  0.306
2006 Reddy CD, Patti R, Guttapalli A, Maris JM, Yanamandra N, Rachamallu A, Sutton LN, Phillips PC, Posner GH. Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma. Journal of Cellular Biochemistry. 97: 198-206. PMID 16200638 DOI: 10.1002/Jcb.20629  0.338
2005 Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM. Chromosome 1p and 11q deletions and outcome in neuroblastoma. The New England Journal of Medicine. 353: 2243-53. PMID 16306521 DOI: 10.1056/Nejmoa052399  0.326
2005 Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Research. 65: 9868-75. PMID 16267010 DOI: 10.1158/0008-5472.Can-04-2426  0.366
2005 George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6466-73. PMID 16116152 DOI: 10.1200/Jco.2005.05.582  0.343
2005 Maris JM, Hii G, Gelfand CA, Varde S, White PS, Rappaport E, Surrey S, Fortina P. Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. Genome Research. 15: 1168-76. PMID 16077016 DOI: 10.1101/Gr.3865305  0.328
2005 Mosse YP, Greshock J, Weber BL, Maris JM. Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era. Cancer Letters. 228: 83-90. PMID 15967571 DOI: 10.1016/J.Canlet.2005.02.052  0.305
2005 Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Letters. 228: 171-179. PMID 15927358 DOI: 10.1016/J.Canlet.2005.01.049  0.366
2005 Morowitz MJ, Barr R, Wang Q, King R, Rhodin N, Pawel B, Zhao H, Erickson SA, Sheppard GS, Wang J, Maris JM, Shusterman S. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2680-5. PMID 15814649 DOI: 10.1158/1078-0432.Ccr-04-1917  0.387
2005 Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Current Opinion in Pediatrics. 17: 7-13. PMID 15659956 DOI: 10.1097/01.Mop.0000150631.60571.89  0.318
2005 Howard JP, Maris JM, Kersun LS, Huberty JP, Cheng SC, Hawkins RA, Matthay KK. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatric Blood & Cancer. 44: 232-9. PMID 15490487 DOI: 10.1002/Pbc.20240  0.313
2004 Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Research. 64: 8816-20. PMID 15604238 DOI: 10.1158/0008-5472.Can-04-1923  0.322
2004 Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer. 11: 423-36. PMID 15369446 DOI: 10.1677/Erc.1.00829  0.366
2004 Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, Maris JM. Germline PHOX2B mutation in hereditary neuroblastoma. American Journal of Human Genetics. 75: 727-30. PMID 15338462 DOI: 10.1086/424530  0.308
2003 Mosse Y, Greshock J, King A, Khazi D, Weber BL, Maris JM. Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. The Lancet. Oncology. 4: 769-71. PMID 14662434 DOI: 10.1016/S1470-2045(03)01283-X  0.324
2003 Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M, Maris JM. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. Journal of Pediatric Hematology Oncology. 25: 769-773. PMID 14528098 DOI: 10.1097/00043426-200310000-00005  0.315
2003 Accorsi R, Morowitz MJ, Charron M, Maris JM. Pinhole imaging 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma Pediatric Radiology. 33: 688-692. PMID 12908090 DOI: 10.1007/S00247-003-1006-6  0.342
2002 Maris JM, Denny CT. Focus on embryonal malignancies. Cancer Cell. 2: 447-50. PMID 12498713 DOI: 10.1016/S1535-6108(02)00206-4  0.358
2001 Hogarty MD, Maris JM, White PS, Guo C, Brodeur GM. Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Medical and Pediatric Oncology. 36: 52-55. PMID 11464906 DOI: 10.1002/1096-911X(20010101)36:1<52::Aid-Mpo1014>3.0.Co;2-8  0.307
2001 White PS, Thompson PM, Seifried BA, Sulman EP, Jensen SJ, Guo C, Maris JM, Hogarty MD, Allen C, Biegel JA, Matise TC, Gregory SG, Reynolds CP, Brodeur GM. Detailed molecular analysis of 1p36 in neuroblastoma. Medical and Pediatric Oncology. 36: 37-41. PMID 11464901 DOI: 10.1002/1096-911X(20010101)36:1<37::Aid-Mpo1010>3.0.Co;2-L  0.338
2001 White PS, Thompson PM, Seifried BA, Sulman EP, Jensen SJ, Guo C, Maris JM, Hogarty MD, Allen C, Biegel JA, Matise TC, Gregory SG, Reynolds CP, Brodeur GM. Comprehensive analysis of chromosome 1p deletions in neuroblastoma Medical and Pediatric Oncology. 36: 32-36. PMID 11464900 DOI: 10.1002/1096-911X(20010101)36:1<32::Aid-Mpo1009>3.0.Co;2-0  0.361
2001 Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, Rajalingam V, Gerbing R, Stram DO, Matthay KK, Seeger RC, Brodeur GM. Loss of heterozygosity for chromosome 14q in neuroblastoma Medical and Pediatric Oncology. 36: 28-31. PMID 11464899 DOI: 10.1002/1096-911X(20010101)36:1<28::Aid-Mpo1008>3.0.Co;2-0  0.32
2001 Thompson PM, Seifried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM, Brodeur GM, Stram DO, Seeger RC, Gerbing R, Matthay KK, Matise TC, White PS. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma Medical and Pediatric Oncology. 36: 24-27. PMID 11464895 DOI: 10.1002/1096-911X(20010101)36:1<24::Aid-Mpo1007>3.0.Co;2-7  0.319
2001 Sulman EP, White PS, Dumanski JP, Maris JM, Brodeur GM. Identification of candidate tumor suppressor genes in meningioma by regional expression profiling Nature Genetics. 27: 89-89. DOI: 10.1038/87318  0.336
2000 Shusterman S, Grupp SA, Maris JM. Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470 Medical and Pediatric Oncology. 35: 673-676. PMID 11107144 DOI: 10.1002/1096-911X(20001201)35:6<673::Aid-Mpo41>3.0.Co;2-O  0.364
2000 Hogarty MD, Liu X, Thompson PM, White PS, Sulman EP, Maris JM, Brodeur GM. BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification. Medical and Pediatric Oncology. 35: 559-62. PMID 11107117 DOI: 10.1002/1096-911X(20001201)35:6<559::Aid-Mpo14>3.0.Co;2-J  0.328
2000 Guo C, White PS, Hogarty MD, Brodeur GM, Gerbing R, Stram DO, Maris JM. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas Medical and Pediatric Oncology. 35: 544-546. PMID 11107113 DOI: 10.1002/1096-911X(20001201)35:6<544::Aid-Mpo10>3.0.Co;2-2  0.324
2000 Hogarty MD, Liu X, Guo C, Thompson PM, Weiss MJ, White PS, Sulman EP, Brodeur GM, Maris JM. Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Medical and Pediatric Oncology. 35: 512-5. PMID 11107105 DOI: 10.1002/1096-911X(20001201)35:6<512::Aid-Mpo2>3.0.Co;2-D  0.343
2000 Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 1888-99. PMID 10784629 DOI: 10.1200/Jco.2000.18.9.1888  0.309
1999 Maris JM, Matthay KK. Molecular Biology of Neuroblastoma Journal of Clinical Oncology. 17: 2264-2264. PMID 10561284 DOI: 10.1200/Jco.1999.17.7.2264  0.351
1999 Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM, Maris JM. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas Oncogene. 18: 4948-4957. PMID 10490829 DOI: 10.1038/Sj.Onc.1202887  0.321
1999 Hogarty MD, Maris JM, White PS, Thompson PM, Prendergast GC, Brodeur GM. #419 Analysis of BIN1, a putative MYCN-interacting tumor suppressor, in neuroblastoma Journal of Pediatric Hematology/Oncology. 21: 326. DOI: 10.1097/00043426-199907000-00088  0.319
1998 Lemire EG, Chodirker BN, Williams GJ, Seargeant LE, Israels SJ, Phillips SM, Nanassy JAD, Maris JM, Yanofsky RA. Familial neuroblastoma: report of a kindred with later age at diagnosis. Journal of Pediatric Hematology Oncology. 20: 489-493. PMID 9787327 DOI: 10.1097/00043426-199809000-00017  0.337
1997 Maris JM, Jensen J, Sulman EP, Beltinger CP, Allen C, Biegel JA, Brodeur GM, White PS. Human Krüppel-related 3 (HKR3): a candidate for the 1p36 neuroblastoma tumour suppressor gene? European Journal of Cancer (Oxford, England : 1990). 33: 1991-6. PMID 9516840 DOI: 10.1016/S0959-8049(97)00279-7  0.34
1997 White PS, Maris JM, Sulman EP, Jensen SJ, Kyemba SM, Beltinger CP, Allen C, Kramer DL, Biegel JA, Brodeur GM. Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 33: 1957-61. PMID 9516832 DOI: 10.1016/S0959-8049(97)00311-0  0.315
1997 Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ, Allen C, Biegel JA, Brodeur GM. Molecular genetic analysis of familial neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 33: 1923-8. PMID 9516825 DOI: 10.1016/S0959-8049(97)00265-7  0.301
1997 Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS. Biology and genetics of human neuroblastomas. Journal of Pediatric Hematology Oncology. 19: 93-101. PMID 9149737 DOI: 10.1097/00043426-199703000-00001  0.374
1996 Beltinger CP, White PS, Maris JM, Sulman EP, Jensen SJ, LePaslier D, Stallard BJ, Goeddel DV, de Sauvage FJ, Brodeur GM. Physical mapping and genomic structure of the human TNFR2 gene. Genomics. 35: 94-100. PMID 8661109 DOI: 10.1006/Geno.1996.0327  0.319
1985 Maris JM, Evans AE, McLaughlin AC, D'Angio GJ, Bolinger L, Manos H, Chance B. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. The New England Journal of Medicine. 312: 1500-5. PMID 3990750 DOI: 10.1056/Nejm198506063122307  0.339
Show low-probability matches.